摘要
目的:总结Denosumab在乳腺癌相关治疗领域的应用研究进展。方法:应用PUBMED和CNKI期刊全文数据库检索系统,以"Denosumab,RANKL,乳腺肿瘤,骨质疏松,骨转移癌"等为关键词,检索2004-2010的相关文献.共检索到英文文献117篇,中文文献2篇,通过查找全文,排除重复研究及与本研究无关的文献,符合条件的21篇文献纳入分析。结果:单克隆抗体Denosumab靶向细胞核因子κB受体活化因子配基(receptor activator of nuclear factor-κB ligand,RANKL),可以特异性地阻断破骨细胞生成及存活,在治疗骨质疏松症及代谢性骨病中表现良好。近年关于Denosumab在乳腺癌治疗领域中的初步研究显示,Denosumab对于改善骨密度及骨质代谢标志等方面,有快速、特异和持久的治疗作用;且未发生治疗相关的严重不良反应。结论:Denosumab对乳腺癌引发骨质破坏确有一定作用,但其长期随访结果以及与常规乳腺癌治疗手段的联合应用价值,仍有待进一步研究。
OBJECTIVE: To summarize the advance of Deno- sumab research in breast cancer treatment. METHODS: By PubMed and CNKI retrieval system, with Denosumab, breast neoplasms, osteoporosis, osseous metastases'as the key words, a total of 117 papers of literatures in English and 2 in Chinese were retrieved from 2004 to 2010. The articles that were repetitive studies and had no relations with the study were excluded, and 21 articles were included in reference study finally. RESULTS: Receptor activator of nuclear factor-kB ligand(RANKL) is found to be an essential mediator of osteoclast differentiation, fun-ction, and survival. The monoelonal antibody Denosumab binds and neutralizes RANKL. Some papers have evaluated the efficacy and safety of De- nosumab in patients with osteo-porosis. Denosumab also is found to inhibit bone mineral resorption and increase bone density in the treatment of bone destruction and bone metastases caused by breast cancer, including reductions in markers of bone turnover, with no relevant severe adverse events. CONCLUSIONS: Denosumab have primarily been documented efficacy and safety as a potential treat- ment for bone destruction associated with breast cancer. Additional clinical trial is needed to completely establish the long-term follow- up survey,and the combination of Denosumab and the current ther- apies of breast cancer.
出处
《中华肿瘤防治杂志》
CAS
2011年第1期78-80,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
乳腺肿瘤
抗体
单克隆
综述文献
breast neoplasms
antibodies, monoclonal
review literature